Affimed tries to convince with seven patients
Luminice-203 yields its first topline data, but where are all the patients?
Adcetris gives Pfizer its first post-Seagen surprise
The Echelon-3 study seemed doomed, but it just read out positively for overall survival.
Affimed looks to reverse a share price collapse
Five years after Affimed switched to NK cell engagers investors will see the fruits of a potentially registrational trial.
